Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase

Clinical Chemistry

Volumn 55, Issue 5, 2009, Pages 986-993

  Gensburger, Olivier ^a,b   Picard, Nicolas ^a,b,c   Marquet, Pierre ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; INOSINATE DEHYDROGENASE; INOSINE PHOSPHATE; MYCOPHENOLATE ACYL GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID PHENYL GLUCURONIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; RECOMBINANT TYPE 2 INOSINE MONOPHOSPHATE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; LIQUID CHROMATOGRAPHY; LYMPHOCYTE; LYMPHOCYTE MEMBRANE; LYMPHOMA CELL; TANDEM MASS SPECTROMETRY;

GLUCURONIDES; HUMANS; IMP DEHYDROGENASE; INHIBITORY CONCENTRATION 50; JURKAT CELLS; KINETICS; MYCOPHENOLIC ACID; RECOMBINANT PROTEINS;

EID: 65949087878     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.113936     Document Type: Article

References (35)

1. Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins: purification and characterization of inhibitor binding. Biochem Pharmacol 1995;49:1323-1329
2. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990;265:5292-5295 (Pubitemid 120014503)
3. Collart FR, Huberman E. Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs. J Biol Chem 1988;263:15769-15772 (Pubitemid 18255598)
4. Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc Natl Acad Sci U S A 1999;96:3531-3536 (Pubitemid 29168943)
5. Wang W, Hedstrom L. Kinetic mechanism of human inosine 5′-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. Biochemistry 1997;36:8479-8483 (Pubitemid 27305130)
6. Gu JJ, Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L, Mitchell BS. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest 2000;106:599-606. (Pubitemid 30666393)
7. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S, Weber G. Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res 1991;51:3886-3890
8. Allison AC, Eugui EM. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant Proc 1993;25:8-18. (Pubitemid 23194146)
9. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118. (Pubitemid 30394534)
10. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-1325
11. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-232
12. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995;17:681-684
13. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004;18:485-492 (Pubitemid 39264342)
14. Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit 1997;19:358-360 (Pubitemid 28053493)
15. Schütz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999;45:419-422 (Pubitemid 29114183)
16. Armstrong VW, Schwabe H, Schmuck B, Scholz C, Wiese C, Bonsack S, Oellerich M. The acylglucuronide of mycophenolic acid forms a specific covalent adduct with inosine monophosphate dehydrogenase 2. [Abstract] Clin Exp Pharmacol Physiol 2004;31:A99.
17. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-455 (Pubitemid 28273453)
18. Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999;65:640-648 (Pubitemid 29294027)
19. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998;9:1511-1520 (Pubitemid 28354563)
20. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14:2381-2386 (Pubitemid 37052386)
21. Pelletier RP, Akin B, Henry ML, Bumgardner GL, Elkhammas EA, Rajab A, Ferguson RM. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003;17:200-205 (Pubitemid 36748465)
22. Van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-266
23. Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008;30:673-683
24. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, et al. Therapeutic monitoring of mycophenolic acid: a consensus panel report. Clin Biochem 1998;31:317-322
25. Squifflet JP, Backman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001;72:63-69
26. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496-2503
27. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58. (Pubitemid 46091591)
28. Prémaud A, Rousseau A, Picard N, Marquet P. Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2006;28:274-277 (Pubitemid 44314962)
29. Prémaud A, Rousseau A, Le Meur Y, Lachâtre G, Marquet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004;26:609-619 (Pubitemid 39579141)
30. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002;48:517-525
31. Brandhorst G, Marquet P, Shaw LM, Liebisch G, Schmitz G, Coffing MJ, et al. Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. Ther Drug Monit 2008;30:428-433
32. Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, Marquet P. Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005;33:139-146 (Pubitemid 40023525)
33. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schütz E, Brenner-Weiss G, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999;126:1075-1082
34. Korecka M, Nikolic D, van Breemen RB, Shaw LM. The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. Clin Chem 1999;45:1047-1050 (Pubitemid 29340542)
35. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993;268:27286-27290 (Pubitemid 24006448)